ClinicalTrials.gg
CompletedNCT00366678Updated Aug 15, 2012Results posted

Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants

A Phase 3 interventional study of 13-valent pneumococcal conjugate vaccine and 7-valent pneumococcal conjugate vaccine in Vaccines, Pneumococcal, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed at 46 sites in France. Open to participants aged 42 Days to 98 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-08-15.

Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
613
Allocation
Randomized
Ages
42 Days to 98 Days
Sex
All
01

Study summary

The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine compared to Prevenar (7vPnC), when given concomitantly with routine pediatric vaccines in France.

02

Conditions studied

  • Vaccines, Pneumococcal

Keywords

  • Safety
  • Vaccine
03

In context

Lead sponsor

Wyeth is now a wholly owned subsidiary of Pfizer is the lead sponsor of 484 studies on the registry; none are open to participants now.

First submitted before Wyeth became part of Pfizer.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
42 Days to 98 Days
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy 2-month-old infants.
  • Available for the entire study period.

Exclusion criteria

Exclusion criteria:

  • Known to vaccines.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
613 participants (actual)

Study arms

  • Experimental
    13-valent pneumococcal conjugate vaccine

    13-valent pneumococcal conjugate vaccine

    Biological: 13-valent pneumococcal conjugate vaccine · Drug: Pentavac

  • Active comparator
    7-valent pneumococcal conjugate vaccine

    7-valent pneumococcal conjugate vaccine

    Biological: 7-valent pneumococcal conjugate vaccine · Drug: Pentavac

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Predefined Antibody Levels for Diphtheria, Tetanus, Hemophilus Influenza Type b (Hib), Poliomyelitis (Type 1, 2, 3), Pertussis Toxin (PT) and Filamentous Hemagglutinin (FHA) in 13vPnC Group Relative to 7vPnC Group

    Percentage of participants achieving predefined antibody threshold levels ≥0.1 IU/mL for diphtheria, ≥0.1 IU/mL for tetanus, ≥ 0.15 μg/mL for Hib polyribosylribitol phosphate (PRP), antibody titer ≥1:8 for polio and ≥5 EU/mL for pertussis (PT and FHA) with the corresponding 95% CI for each concomitant antigen are presented.

    Time frame: One Month After the 3-Dose Infant Series (at 5 months of age) and the Toddler Dose (at 13 months of age)

  2. Geometric Mean Concentration (GMC) as Measured by Enzyme-linked Immunosorbent Assay (ELISA) for Diphtheria Toxoid and Tetanus Toxoid in 13vPnC Group Relative to 7vPnC Group

    Time frame: One month after the 3-Dose Infant Series (at 5 months of age) and the Toddler Dose (at 13 months of age)

  3. Geometric Mean Concentration (GMC) for Haemophilus Influenzae Type b (Hib) in 13vPnC Group Relative to 7vPnC Group

    Time frame: One month after the 3-Dose Infant Series (at 5 months of age) and the Toddler Dose (at 13 months of age)

  4. Geometric Mean Concentration (GMC) as Measured by Enzyme-linked Immunosorbent Assay (ELISA) for Poliomyelitis (Type 1, Type 2 and Type 3) in 13vPnC Group Relative to 7vPnC Group

    Time frame: One month after the 3-Dose Infant Series (at 5 months of age) and the Toddler Dose (at 13 months of age)

  5. Geometric Mean Concentration (GMC) as Measured by ELISA for Pertussis Toxin (PT) and Pertussis Filamentous Hemagglutinin (FHA) in 13vPnC Group Relative to 7vPnC Group

    Time frame: One month after the 3-Dose Infant Series (at 5 months of age) and the Toddler Dose (at 13 months of age)

  6. Percentage of Participants Achieving a Pneumococcal Antibody Level ≥0.35µg/mL (ELISA) After the 3-Dose Infant Series of 13vPnC

    Percentages of participants achieving World Health Organization (WHO) predefined antibody threshold ≥0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

    Time frame: One month after the 3-Dose Infant Series (at 5 months of age)

  7. Percentage of Participants Reporting Pre-Specified Local Reactions

    Local reactions were collected using an electronic diary. Tenderness (Tender)was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (Sev) (\>7.0 cm). Participants may be represented in more than 1 category.

    Time frame: During the 4-day period after each dose

  8. Percentage of Participants Reporting Pre-Specified Systemic Events

    Systemic events (fever \[fv\] ≥ 37.5 degrees Celsius \[C\], fever ≥ 38 C but ≤ 39 C, fever \>39 C but ≤ 40 C, fever \> 40 C, decreased \[decr\] appetite, irritability, increased \[incr\] sleep, decreased sleep, hives, use of medication \[med\] to treat symptoms \[sx\], and use of medication to prevent symptoms) were reported using an electronic diary. Participants may be represented in more than 1 category.

    Time frame: During the 4-day period after each dose

  9. Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After the 3-Dose Infant Series of 13vPnC

    Antibody GMC for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% confidence intervals (CI) were evaluated.

    Time frame: One month after the 3-Dose Infant Series (at 5 months of age)

Secondary outcomes

  1. Percentage of Participants Achieving a Pneumococcal Antibody Level ≥0.35µg/mL (ELISA) After the Toddler Dose in the 13vPnC/13vPnC, 7vPnC/7vPnC and 7vPnC/13vPnC Groups

    Percentages of participants achieving World health Organization (WHO) predefined antibody threshold ≥0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

    Time frame: One month after the toddler dose (at 13 months of age)

  2. Pneumococcal Geometric Mean Concentration (GMC) Before and After the Toddler Dose in the 13vPnC/13vPnC, 7vPnC/7vPnC and 7vPnC/13vPnC Groups

    Antibody GMC as measured by ELISA for 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

    Time frame: One month after the Toddler Dose (at 13 months of age)

  3. Percentage of Participants Achieving Antibody Titer ≥1:8 After the Toddler Dose in 13vPnC/13vPnC and 7vPnC/13vPnC Groups

    Percentage of participants achieving functional antibody titer ≥1:8 as measured by opsonophagocytic activity assay (OPA) along with the corresponding 95% CI for the 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

    Time frame: One month after the toddler dose (at 13 months of age)

  4. Geometric Mean Titer (GMT) in 13vPnC/13vPnC and 7vPnC/13vPnC Groups After the Toddler Dose

    GMT as measured by opsonophagocytic activity assay (OPA) for 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

    Time frame: One month after the toddler dose (at 13 months of age)

07

Results

Posted Aug 15, 2012

Participant flow

Participants were recruited in France from October 2006 to July 2007.

Infant Series
Participant flow — Infant Series
Milestone13vPnC/13vPnC Vaccine7vPnC/7vPnC Vaccine7vPnC/13vPnC Vaccine
Started3043090
Vaccinated dose 13023090
Vaccinated dose 22953040
Vaccinated dose 32913020
Completed2902990
Not completed14100
Withdrew: Withdrawal by subject860
Withdrew: Protocol violation430
Withdrew: Failed to return110
Withdrew: Adverse event100
After Infant
Participant flow — After Infant
Milestone13vPnC/13vPnC Vaccine7vPnC/7vPnC Vaccine7vPnC/13vPnC Vaccine
Started2902990
Completed2732890
Not completed17100
Withdrew: Withdrawal by subject840
Withdrew: Lost to follow-up210
Withdrew: Failed to return550
Withdrew: Adverse event100
Withdrew: Protocol violation100
Toddler Dose
Participant flow — Toddler Dose
Milestone13vPnC/13vPnC Vaccine7vPnC/7vPnC Vaccine7vPnC/13vPnC Vaccine
Started273152137
Completed268151137
Not completed510
Withdrew: Protocol violation210
Withdrew: Failed to return100
Withdrew: Withdrawal by subject100
Withdrew: Protocol deviation100

Outcome measures

PrimaryPercentage of Participants Achieving Predefined Antibody Levels for Diphtheria, Tetanus, Hemophilus Influenza Type b (Hib), Poliomyelitis (Type 1, 2, 3), Pertussis Toxin (PT) and Filamentous Hemagglutinin (FHA) in 13vPnC Group Relative to 7vPnC Group

Percentage of participants achieving predefined antibody threshold levels ≥0.1 IU/mL for diphtheria, ≥0.1 IU/mL for tetanus, ≥ 0.15 μg/mL for Hib polyribosylribitol phosphate (PRP), antibody titer ≥1:8 for polio and ≥5 EU/mL for pertussis (PT and FHA) with the corresponding 95% CI for each concomitant antigen are presented.

Time frame:
One Month After the 3-Dose Infant Series (at 5 months of age) and the Toddler Dose (at 13 months of age)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Predefined Antibody Levels for Diphtheria, Tetanus, Hemophilus Influenza Type b (Hib), Poliomyelitis (Type 1, 2, 3), Pertussis Toxin (PT) and Filamentous Hemagglutinin (FHA) in 13vPnC Group Relative to 7vPnC Group
percentage of participants13vPnC After the Infant Series7vPnC After the Infant Series13vPnC After the Toddler Dose7vPnC After the Toddler Dose
Pertussis - PT Infant ≥5 Toddler 5 (EU/mL)100.0 (98.6 to 100.0)100.0 (98.6 to 100.0)100.0 (98.5 to 100.0)100.0 (97.3 to 100.0)
Pertussis - PT Infant ≥26 Toddler 17 (EU/mL)94.3 (90.8 to 96.8)95.0 (91.7 to 97.3)98.3 (95.8 to 99.5)96.2 (91.4 to 98.8)
Pertussis - FHA Infant ≥5 Toddler 5 (EU/mL)100.0 (98.6 to 100.0)100.0 (98.6 to 100.0)100.0 (98.5 to 100.0)100.0 (97.3 to 100.0)
Pertussis - FHA Infant ≥7.82 Toddler 7.82 (EU/mL)100.0 (98.6 to 100.0)100.0 (98.6 to 100.0)100.0 (98.5 to 100.0)100.0 (97.3 to 100.0)
Pertussis - FHA Infant ≥36.00 Toddler 75 (EU/mL)93.5 (89.9 to 96.2)95.8 (92.6 to 97.9)92.5 (88.4 to 95.5)95.5 (90.4 to 98.3)
Diphtheria 0.1 (IU/mL)76.5 (70.9 to 81.5)84.6 (79.6 to 88.7)99.2 (97.0 to 99.9)100 (97.3 to 100.0)
Diphtheria 0.01 (IU/mL)100.0 (98.6 to 100.0)100.0 (98.6 to 100.0)100.0 (98.5 to 100.0)100.0 (97.3 to 100.0)
Tetanus 0.1 (IU/mL)84.9 (80.0 to 89.1)82.2 (76.9 to 86.7)96.2 (93.0 to 98.3)98.5 (94.7 to 99.8)
Tetanus 0.01 (IU/mL)100.0 (98.6 to 100.0)100.0 (98.6 to 100.0)100.0 (98.5 to 100.0)100.0 (97.3 to 100.0)
Polio Type 1 (1:8)88.8 (84.3 to 92.3)91.0 (86.8 to 94.2)97.9 (95.2 to 99.3)98.4 (94.5 to 99.8)
Polio Type 2 (1:8)77.7 (72.1 to 82.6)82.0 (76.8 to 86.5)98.7 (96.4 to 99.7)99.2 (95.8 to 100.0)
Polio Type 3 (1:8)92.6 (88.7 to 95.5)93.0 (89.1 to 95.8)99.2 (97.0 to 99.9)100.0 (97.2 to 100.0)
Hib (PRP) 0.15 (μg/mL)95.5 (92.1 to 97.7)94.6 (91.0 to 97.1)100.0 (98.5 to 100.0)100.0 (97.2 to 100.0)
Hib (PRP) 1.0 (μg/mL)58.6 (52.1 to 64.9)63.1 (56.6 to 69.2)97.9 (95.2 to 99.3)97.7 (93.5 to 99.5)
Statistical analysis
  • 13vPnC After the Infant Series vs 7vPnC After the Infant Series · Difference: 0.0 · 95% CI -1.4 to 1.4
  • 13vPnC After the Infant Series vs 7vPnC After the Infant Series · Difference: -0.7 · 95% CI -4.8 to 3.3
  • 13vPnC After the Infant Series vs 7vPnC After the Infant Series · Difference: 0.0 · 95% CI -1.4 to 1.4
  • 13vPnC After the Infant Series vs 7vPnC After the Infant Series · Difference: -2.3 · 95% CI -6.4 to 1.7
  • 13vPnC After the Infant Series vs 7vPnC After the Infant Series · Difference: 0.0 · 95% CI -1.4 to 1.4
  • 13vPnC After the Toddler Dose vs 7vPnC After the Toddler Dose · Difference: 0.0 · 95% CI -1.7 to 2.7
  • 13vPnC After the Toddler Dose vs 7vPnC After the Toddler Dose · Difference: 2.1 · 95% CI -1.4 to 6.8
  • 13vPnC After the Toddler Dose vs 7vPnC After the Toddler Dose · Difference: 0.0 · 95% CI -1.7 to 2.7
  • 13vPnC After the Toddler Dose vs 7vPnC After the Toddler Dose · Difference: 0.0 · 95% CI -1.7 to 2.7
  • 13vPnC After the Toddler Dose vs 7vPnC After the Toddler Dose · Difference: -3.0 · 95% CI -8.0 to 2.5
  • 13vPnC After the Infant Series vs 7vPnC After the Infant Series · Difference: -8.0 · 95% CI -14.9 to -1.2
  • 13vPnC After the Infant Series vs 7vPnC After the Infant Series · Difference: 0.0 · 95% CI -1.4 to 1.4
  • 13vPnC After the Infant Series vs 7vPnC After the Infant Series · Difference: 2.7 · 95% CI -3.7 to 9.2
  • 13vPnC After the Infant Series vs 7vPnC After the Infant Series · Difference: 0.0 · 95% CI -1.5 to 1.5
  • 13vPnC After the Toddler Dose vs 7vPnC After the Toddler Dose · Difference: -0.8 · 95% CI -3.1 to 1.8
  • 13vPnC After the Toddler Dose vs 7vPnC After the Toddler Dose · Difference: 0.0 · 95% CI -1.7 to 2.7
  • 13vPnC After the Toddler Dose vs 7vPnC After the Toddler Dose · Difference: -2.3 · 95% CI -5.8 to 1.8
  • 13vPnC After the Toddler Dose vs 7vPnC After the Toddler Dose · Difference: 0.0 · 95% CI -1.7 to 2.7
  • 13vPnC After the Infant Series vs 7vPnC After the Infant Series · Difference: -2.3 · 95% CI -7.6 to 3.0
  • 13vPnC After the Infant Series vs 7vPnC After the Infant Series · Difference: -4.3 · 95% CI -11.4 to 2.6
  • 13vPnC After the Infant Series vs 7vPnC After the Infant Series · Difference: -0.3 · 95% CI -5.0 to 4.3
  • 13vPnC After the Toddler Dose vs 7vPnC After the Toddler Dose · Difference: -0.5 · 95% CI -3.6 to 3.5
  • 13vPnC After the Toddler Dose vs 7vPnC After the Toddler Dose · Difference: -0.5 · 95% CI -3.1 to 3.0
  • 13vPnC After the Toddler Dose vs 7vPnC After the Toddler Dose · Difference: -0.8 · 95% CI -3.1 to 1.9
  • 13vPnC After the Infant Series vs 7vPnC After the Infant Series · Difference: 0.9 · 95% CI -3.2 to 5.0
  • 13vPnC After the Infant Series vs 7vPnC After the Infant Series · Difference: -4.5 · 95% CI -13.2 to 4.4
  • 13vPnC After the Toddler Dose vs 7vPnC After the Toddler Dose · Difference: 0.0 · 95% CI -1.7 to 2.8
  • 13vPnC After the Toddler Dose vs 7vPnC After the Toddler Dose · Difference: 0.2 · 95% CI -3.1 to 4.5
SecondaryPercentage of Participants Achieving a Pneumococcal Antibody Level ≥0.35µg/mL (ELISA) After the Toddler Dose in the 13vPnC/13vPnC, 7vPnC/7vPnC and 7vPnC/13vPnC Groups

Percentages of participants achieving World health Organization (WHO) predefined antibody threshold ≥0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

Time frame:
One month after the toddler dose (at 13 months of age)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Pneumococcal Antibody Level ≥0.35µg/mL (ELISA) After the Toddler Dose in the 13vPnC/13vPnC, 7vPnC/7vPnC and 7vPnC/13vPnC Groups
percentage of participants13vPnC Infant Series / 13vPnC Toddler Dose7vPnC Infant Series / 7vPnC Toddler Dose7vPnC Infant Series / 13vPnC Toddler Dose
Common Serotypes - Serotype 4 (n=233,126,111)100.0 (98.4 to 100.0)100.0 (97.1 to 100.0)99.1 (95.1 to 100.0)
Common Serotypes - Serotype 6B (n=233,126,108)99.6 (97.6 to 100.0)99.2 (95.7 to 100.0)98.1 (93.5 to 99.8)
Common Serotypes - Serotype 9V (n=232,124,109)100.0 (98.4 to 100.0)100.0 (97.1 to 100.0)100.0 (96.7 to 100.0)
Common Serotypes - Serotype 14 (n=233,135,111)99.6 (97.6 to 100.0)100.0 (97.1 to 100.0)99.1 (95.1 to 100.0)
Common Serotypes - Serotype 18C (n=230,125,113)99.6 (97.6 to 100.0)99.2 (95.6 to 100.0)98.2 (93.8 to 99.8)
Common Serotypes - Serotype 19F (n=233,126,112)97.9 (95.1 to 99.3)97.6 (93.2 to 99.5)97.3 (92.4 to 99.4)
Common Serotypes - Serotype 23F (n=232,123,111)99.6 (97.6 to 100.0)99.2 (95.6 to 100.0)99.1 (95.1 to 100.0)
Additional Serotypes - Serotype 1 (n=233,119,112)100.0 (98.4 to 100.0)0.8 (0.0 to 4.6)95.5 (89.9 to 98.5)
Additional Serotypes - Serotype 3 (n=233,124,113)94.8 (91.2 to 97.3)13.7 (8.2 to 21.0)93.8 (87.7 to 97.5)
Additional Serotypes - Serotype 5 (n=236,111,111)100.0 (98.4 to 100.0)73.0 (63.7 to 81.0)90.1 (83.0 to 94.9)
Additional Serotypes - Serotype 6A (n=235,124,109)100.0 (98.4 to 100.0)89.5 (82.7 to 94.3)89.9 (82.7 to 94.9)
Additional Serotypes - Serotype 7F (n=234,124,110)100.0 (98.4 to 100.0)7.3 (3.4 to 13.3)100.0 (96.7 to 100.0)
Additional Serotypes - Serotype 19A(n=233,127,112)100.0 (98.4 to 100.0)100.0 (97.1 to 100.0)100.0 (96.8 to 100.0)
Statistical analysis
  • 13vPnC Infant Series / 13vPnC Toddler Dose vs 7vPnC Infant Series / 7vPnC Toddler Dose · Difference: 0.0 · 95% CI -1.7 to 2.9
  • 13vPnC Infant Series / 13vPnC Toddler Dose vs 7vPnC Infant Series / 13vPnC Toddler Dose · Difference: 0.9 · 95% CI -0.9 to 4.9
  • 7vPnC Infant Series / 7vPnC Toddler Dose vs 7vPnC Infant Series / 13vPnC Toddler Dose · Difference: -0.9 · 95% CI -4.9 to 2.1
  • 13vPnC Infant Series / 13vPnC Toddler Dose vs 7vPnC Infant Series / 7vPnC Toddler Dose · Difference: 0.4 · 95% CI -1.8 to 3.8
  • 13vPnC Infant Series / 13vPnC Toddler Dose vs 7vPnC Infant Series / 13vPnC Toddler Dose · Difference: 1.4 · 95% CI -1.1 to 5.9
  • 7vPnC Infant Series / 7vPnC Toddler Dose vs 7vPnC Infant Series / 13vPnC Toddler Dose · Difference: -1.1 · 95% CI -5.8 to 2.7
  • 13vPnC Infant Series / 13vPnC Toddler Dose vs 7vPnC Infant Series / 7vPnC Toddler Dose · Difference: 0.0 · 95% CI -1.7 to 2.9
  • 13vPnC Infant Series / 13vPnC Toddler Dose vs 7vPnC Infant Series / 13vPnC Toddler Dose · Difference: 0.0 · 95% CI -1.8 to 3.3
  • 7vPnC Infant Series / 7vPnC Toddler Dose vs 7vPnC Infant Series / 13vPnC Toddler Dose · Difference: 0.0 · 95% CI -3.3 to 3.0
  • 13vPnC Infant Series / 13vPnC Toddler Dose vs 7vPnC Infant Series / 7vPnC Toddler Dose · Difference: -0.4 · 95% CI -2.5 to 2.4
  • 13vPnC Infant Series / 13vPnC Toddler Dose vs 7vPnC Infant Series / 13vPnC Toddler Dose · Difference: 0.5 · 95% CI -1.8 to 4.4
  • 7vPnC Infant Series / 7vPnC Toddler Dose vs 7vPnC Infant Series / 13vPnC Toddler Dose · Difference: -0.9 · 95% CI -4.9 to 2.1
  • 13vPnC Infant Series / 13vPnC Toddler Dose vs 7vPnC Infant Series / 7vPnC Toddler Dose · Difference: 0.4 · 95% CI -1.8 to 3.8
  • 13vPnC Infant Series / 13vPnC Toddler Dose vs 7vPnC Infant Series / 13vPnC Toddler Dose · Difference: 1.3 · 95% CI -1.1 to 5.7
  • 7vPnC Infant Series / 7vPnC Toddler Dose vs 7vPnC Infant Series / 13vPnC Toddler Dose · Difference: -1.0 · 95% CI -5.5 to 2.8
  • 13vPnC Infant Series / 13vPnC Toddler Dose vs 7vPnC Infant Series / 7vPnC Toddler Dose · Difference: 0.2 · 95% CI -3.1 to 4.7
  • 13vPnC Infant Series / 13vPnC Toddler Dose vs 7vPnC Infant Series / 13vPnC Toddler Dose · Difference: 0.5 · 95% CI -2.9 to 5.4
  • 7vPnC Infant Series / 7vPnC Toddler Dose vs 7vPnC Infant Series / 13vPnC Toddler Dose · Difference: -0.3 · 95% CI -5.5 to 4.4
  • 13vPnC Infant Series / 13vPnC Toddler Dose vs 7vPnC Infant Series / 7vPnC Toddler Dose · Difference: 0.4 · 95% CI -1.8 to 3.9
  • 13vPnC Infant Series / 13vPnC Toddler Dose vs 7vPnC Infant Series / 13vPnC Toddler Dose · Difference: 0.5 · 95% CI -1.9 to 4.4
  • 7vPnC Infant Series / 7vPnC Toddler Dose vs 7vPnC Infant Series / 13vPnC Toddler Dose · Difference: -0.1 · 95% CI -4.1 to 3.7
SecondaryPneumococcal Geometric Mean Concentration (GMC) Before and After the Toddler Dose in the 13vPnC/13vPnC, 7vPnC/7vPnC and 7vPnC/13vPnC Groups

Antibody GMC as measured by ELISA for 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

Time frame:
One month after the Toddler Dose (at 13 months of age)
Reported as:
Geometric mean · μg/mL
Pneumococcal Geometric Mean Concentration (GMC) Before and After the Toddler Dose in the 13vPnC/13vPnC, 7vPnC/7vPnC and 7vPnC/13vPnC Groups
μg/mL13vPnC/13vPnC Before Toddler Dose13vPnC/13vPnC After Toddler Dose7vPnC/7vPnC Before Toddler Dose7vPnC/7vPnC After Toddler Dose7vPnC/13vPnC Before Toddler Dose7vPnC/13vPnC After Toddler Dose
Common - Serotype 4 (n=239,233,131,126,118,111)0.3 (0.3 to 0.3)4.2 (3.8 to 4.7)0.5 (0.4 to 0.5)4.8 (4.2 to 5.6)0.5 (0.4 to 0.5)4.0 (3.4 to 4.8)
Common - Serotype 6B (n=235,233,131,126,115,108)1.0 (0.9 to 1.1)9.0 (8.0 to 10.1)1.1 (0.9 to 1.3)9.6 (8.3 to 11.2)0.9 (0.8 to 1.1)10.3 (8.2 to 13.0)
Common - Serotype 9V (n=239,232,131,124,118,109)0.4 (0.4 to 0.5)2.3 (2.3 to 2.8)0.5 (0.5 to 0.6)3.2 (2.8 to 3.7)0.4 (0.4 to 0.5)2.3 (2.0 to 2.6)
Common - Serotype 14 (n=238,233,131,125,118,111)2.0 (1.8 to 2.3)9.5 (8.5 to 10.6)2.4 (2.1 to 2.9)10.8 (9.4 to 12.5)2.4 (2.0 to 3.0)7.8 (6.6 to 9.3)
Common - Serotype 18C (n=239,230,131,125,118,113)0.3 (0.3 to 0.3)2.3 (2.1 to 2.5)0.3 (0.3 to 0.4)2.8 (2.5 to 3.2)0.3 (0.3 to 0.4)2.4 (2.0 to 2.9)
Common - Serotype 19F (n=239,233,130,126,118,112)0.7 (0.6 to 0.7)5.2 (4.5 to 6.0)0.7 (0.6 to 0.9)4.1 (3.4 to 5.0)0.6 (0.5 to 0.7)3.7 (3.0 to 4.6)
Common - Serotype 23F (n=237,232,130,123,118,111)0.3 (0.2 to 0.3)3.0 (2.7 to 3.4)0.3 (0.3 to 0.4)3.7 (3.1 to 4.3)0.3 (0.2 to 0.4)3.1 (2.6 to 3.7)
Additional-Serotype 1 (n=239,233,128,119,116,112)0.4 (0.4 to 0.5)4.1 (3.7 to 4.5)0.0 (0.0 to 0.0)0.0 (0.0 to 0.0)0.0 (0.0 to 0.0)1.8 (1.5 to 2.2)
Additional-Serotype 3 (n=232,233,128,124,115,113)0.2 (0.2 to 0.2)1.0 (0.9 to 1.1)0.1 (0.1 to 0.1)0.1 (0.1 to 0.1)0.1 (0.1 to 0.1)1.3 (1.1 to 1.5)
Additional-Serotype 5 (n=236,236,128,124,115,113)0.8 (0.7 to 0.9)3.3 (3.0 to 3.7)0.4 (0.4 to 0.5)0.5 (0.4 to 0.6)0.4 (0.4 to 0.5)1.1 (1.0 to 1.3)
Additional-Serotype 6A (n=238,235,122,124,116,109)0.9 (0.8 to 1.0)6.1 (5.5 to 6.8)0.4 (0.3 to 0.5)1.5 (1.3 to 1.9)0.4 (0.3 to 0.4)2.6 (2.0 to 3.4)
Additional-Serotype 7F (n=239,234,131,124,117,110)0.8 (0.7 to 0.9)4.5 (4.1 to 5.0)0.1 (0.0 to 0.1)0.1 (0.0 to 0.1)0.1 (0.1 to 0.1)3.7 (3.2 to 4.3)
Additional-Serotype 19A(n=237,233,131,127,117,112)1.5 (1.3 to 1.7)9.5 (8.5 to 10.6)1.1 (0.9 to 1.3)4.0 (3.5 to 4.5)0.9 (0.7 to 1.1)5.3 (4.6 to 6.2)
Statistical analysis
  • 13vPnC/13vPnC After Toddler Dose vs 7vPnC/7vPnC After Toddler Dose · Ratio: 0.87 · 95% CI 0.73 to 1.03
  • 7vPnC/7vPnC After Toddler Dose vs 7vPnC/13vPnC After Toddler Dose · Ratio: 0.83 · 95% CI 0.67 to 1.03
  • 13vPnC/13vPnC After Toddler Dose vs 7vPnC/13vPnC After Toddler Dose · Ratio: 1.04 · 95% CI 0.86 to 1.26
  • 13vPnC/13vPnC After Toddler Dose vs 7vPnC/7vPnC After Toddler Dose · Ratio: 0.93 · 95% CI 0.77 to 1.13
  • 7vPnC/7vPnC After Toddler Dose vs 7vPnC/13vPnC After Toddler Dose · Ratio: 1.07 · 95% CI 0.82 to 1.40
  • 13vPnC/13vPnC After Toddler Dose vs 7vPnC/13vPnC After Toddler Dose · Ratio: 0.87 · 95% CI 0.69 to 1.10
  • 13vPnC/13vPnC After Toddler Dose vs 7vPnC/7vPnC After Toddler Dose · Ratio: 0.80 · 95% CI 0.68 to 0.94
  • 7vPnC/7vPnC After Toddler Dose vs 7vPnC/13vPnC After Toddler Dose · Ratio: 0.71 · 95% CI 0.59 to 0.85
  • 13vPnC/13vPnC After Toddler Dose vs 7vPnC/13vPnC After Toddler Dose · Ratio: 1.13 · 95% CI 0.95 to 1.33
  • 13vPnC/13vPnC After Toddler Dose vs 7vPnC/7vPnC After Toddler Dose · Ratio: 0.88 · 95% CI 0.73 to 1.06
  • 7vPnC/7vPnC After Toddler Dose vs 7vPnC/13vPnC After Toddler Dose · Ratio: 0.72 · 95% CI 0.58 to 0.90
  • 13vPnC/13vPnC After Toddler Dose vs 7vPnC/13vPnC After Toddler Dose · Ratio: 1.22 · 95% CI 1.00 to 1.49
  • 13vPnC/13vPnC After Toddler Dose vs 7vPnC/7vPnC After Toddler Dose · Ratio: 0.82 · 95% CI 0.69 to 0.97
  • 7vPnC/7vPnC After Toddler Dose vs 7vPnC/13vPnC After Toddler Dose · Ratio: 0.86 · 95% CI 0.69 to 1.08
  • 13vPnC/13vPnC After Toddler Dose vs 7vPnC/13vPnC After Toddler Dose · Ratio: 0.95 · 95% CI 0.78 to 1.15
  • 13vPnC/13vPnC After Toddler Dose vs 7vPnC/7vPnC After Toddler Dose · Ratio: 1.26 · 95% CI 1.00 to 1.59
  • 7vPnC/7vPnC After Toddler Dose vs 7vPnC/13vPnC After Toddler Dose · Ratio: 0.91 · 95% CI 0.68 to 1.20
  • 13vPnC/13vPnC After Toddler Dose vs 7vPnC/13vPnC After Toddler Dose · Ratio: 1.39 · 95% CI 1.08 to 1.79
  • 13vPnC/13vPnC After Toddler Dose vs 7vPnC/7vPnC After Toddler Dose · Ratio: 0.81 · 95% CI 0.67 to 1.00
  • 7vPnC/7vPnC After Toddler Dose vs 7vPnC/13vPnC After Toddler Dose · Ratio: 0.85 · 95% CI 0.67 to 1.07
  • 13vPnC/13vPnC After Toddler Dose vs 7vPnC/13vPnC After Toddler Dose · Ratio: 0.96 · 95% CI 0.78 to 1.19
SecondaryPercentage of Participants Achieving Antibody Titer ≥1:8 After the Toddler Dose in 13vPnC/13vPnC and 7vPnC/13vPnC Groups

Percentage of participants achieving functional antibody titer ≥1:8 as measured by opsonophagocytic activity assay (OPA) along with the corresponding 95% CI for the 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

Time frame:
One month after the toddler dose (at 13 months of age)
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving Antibody Titer ≥1:8 After the Toddler Dose in 13vPnC/13vPnC and 7vPnC/13vPnC Groups
Percentage of Participants13vPnC/13vPnC After Toddler Dose7vPnC/13vPnC After Toddler Dose
Additional Serotypes - Serotype 1100.0 (95.9 to 100.0)98.9 (94.0 to 100.0)
Additional Serotypes - Serotype 3100.0 (95.9 to 100.0)97.8 (92.2 to 99.7)
Additional Serotypes - Serotype 5100.0 (95.9 to 100.0)97.8 (92.2 to 99.7)
Additional Serotypes - Serotype 6A100.0 (95.8 to 100.0)98.9 (94.0 to 100.0)
Additional Serotypes - Serotype 7F100.0 (95.8 to 100.0)100.0 (95.9 to 100.0)
Additional Serotypes - Serotype 19A98.8 (93.7 to 100.0)97.8 (92.2 to 99.7)
SecondaryGeometric Mean Titer (GMT) in 13vPnC/13vPnC and 7vPnC/13vPnC Groups After the Toddler Dose

GMT as measured by opsonophagocytic activity assay (OPA) for 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

Time frame:
One month after the toddler dose (at 13 months of age)
Reported as:
Geometric mean · titer
Geometric Mean Titer (GMT) in 13vPnC/13vPnC and 7vPnC/13vPnC Groups After the Toddler Dose
titer13vPnC/13vPnC After Toddler Dose7vPnC/13vPnC After Toddler Dose
Additional Serotypes - Serotype 1126.00 (99.87 to 158.97)61.58 (47.72 to 79.47)
Additional Serotypes - Serotype 3345.33 (296.06 to 402.80)428.88 (346.69 to 530.56)
Additional Serotypes - Serotype 5244.18 (200.14 to 297.92)130.99 (103.68 to 165.50)
Additional Serotypes - Serotype 6A1346.83 (1143.98 to 1585.65)891.44 (694.76 to 1143.81)
Additional Serotypes - Serotype 7F8126.24 (6657.36 to 9919.21)17034.59 (14316.59 to 20268.60)
Additional Serotypes - Serotype 19A804.06 (615.90 to 1049.71)1072.43 (799.06 to 1439.32)
PrimaryGeometric Mean Concentration (GMC) as Measured by Enzyme-linked Immunosorbent Assay (ELISA) for Diphtheria Toxoid and Tetanus Toxoid in 13vPnC Group Relative to 7vPnC Group
Time frame:
One month after the 3-Dose Infant Series (at 5 months of age) and the Toddler Dose (at 13 months of age)
Reported as:
Geometric mean · IU/mL
Geometric Mean Concentration (GMC) as Measured by Enzyme-linked Immunosorbent Assay (ELISA) for Diphtheria Toxoid and Tetanus Toxoid in 13vPnC Group Relative to 7vPnC Group
IU/mL13vPnC After the Infant Series7vPnC After the Infant Series13vPnC After the Toddler Dose7vPnC After the Toddler Dose
Diphtheria0.19 (0.17 to 0.21)0.24 (0.22 to 0.27)2.09 (1.87 to 2.34)2.60 (2.26 to 2.99)
Tetanus0.20 (0.18 to 0.22)0.21 (0.19 to 0.23)1.08 (0.94 to 1.24)1.25 (1.05 to 1.47)
Statistical analysis
  • 13vPnC After the Infant Series vs 7vPnC After the Infant Series · Ratio: 0.77 · 95% CI 0.66 to 0.90
  • 13vPnC After the Infant Series vs 7vPnC After the Infant Series · Ratio: 0.94 · 95% CI 0.82 to 1.08
  • 13vPnC After the Toddler Dose vs 7vPnC After the Toddler Dose · Ratio: 0.80 · 95% CI 0.67 to 0.97
  • 13vPnC After the Toddler Dose vs 7vPnC After the Toddler Dose · Ratio: 0.86 · 95% CI 0.69 to 1.08
PrimaryGeometric Mean Concentration (GMC) for Haemophilus Influenzae Type b (Hib) in 13vPnC Group Relative to 7vPnC Group
Time frame:
One month after the 3-Dose Infant Series (at 5 months of age) and the Toddler Dose (at 13 months of age)
Reported as:
Number · μg/mL
Geometric Mean Concentration (GMC) for Haemophilus Influenzae Type b (Hib) in 13vPnC Group Relative to 7vPnC Group
μg/mL13vPnC After the Infant Series7vPnC After the Infant Series13vPnC After the Toddler Dose7vPnC After the Toddler Dose
Geometric Mean Concentration (GMC) for Haemophilus Influenzae Type b (Hib) in 13vPnC Group Relative to 7vPnC Group1.28 (1.10 to 1.49)1.40 (1.19 to 1.64)12.15 (10.54 to 14.00)11.68 (9.66 to 14.13)
Statistical analysis
  • 13vPnC After the Infant Series vs 7vPnC After the Infant Series · Ratio: 0.91 · 95% CI 0.73 to 1.14
  • 13vPnC After the Toddler Dose vs 7vPnC After the Toddler Dose · Ratio: 1.04 · 95% CI 0.82 to 1.32
PrimaryGeometric Mean Concentration (GMC) as Measured by Enzyme-linked Immunosorbent Assay (ELISA) for Poliomyelitis (Type 1, Type 2 and Type 3) in 13vPnC Group Relative to 7vPnC Group
Time frame:
One month after the 3-Dose Infant Series (at 5 months of age) and the Toddler Dose (at 13 months of age)
Reported as:
Number · titer
Geometric Mean Concentration (GMC) as Measured by Enzyme-linked Immunosorbent Assay (ELISA) for Poliomyelitis (Type 1, Type 2 and Type 3) in 13vPnC Group Relative to 7vPnC Group
titer13vPnC After the Infant Series7vPnC After the Infant Series13vPnC After the Toddler Dose7vPnC After the Toddler Dose
Polio Type 124.99 (21.37 to 29.23)28.33 (24.40 to 32.89)253.05 (207.15 to 309.11)250.56 (193.17 to 324.99)
Polio Type 217.75 (15.07 to 20.92)21.55 (18.43 to 25.20)408.34 (338.94 to 491.95)415.20 (325.57 to 529.52)
Polio Type 341.08 (34.08 to 49.52)52.95 (43.26 to 64.82)536.32 (436.46 to 659.02)638.18 (501.50 to 812.13)
Statistical analysis
  • 13vPnC After the Infant Series vs 7vPnC After the Infant Series · Ratio: 0.88 · 95% CI 0.71 to 1.09
  • 13vPnC After the Infant Series vs 7vPnC After the Infant Series · Ratio: 0.82 · 95% CI 0.66 to 1.03
  • 13vPnC After the Infant Series vs 7vPnC After the Infant Series · Ratio: 0.78 · 95% CI 0.59 to 1.02
  • 13vPnC After the Toddler Dose vs 7vPnC After the Toddler Dose · Ratio: 1.01 · 95% CI 0.72 to 1.41
  • 13vPnC After the Toddler Dose vs 7vPnC After the Toddler Dose · Ratio: 0.98 · 95% CI 0.72 to 1.34
  • 13vPnC After the Toddler Dose vs 7vPnC After the Toddler Dose · Ratio: 0.84 · 95% CI 0.60 to 1.17
PrimaryGeometric Mean Concentration (GMC) as Measured by ELISA for Pertussis Toxin (PT) and Pertussis Filamentous Hemagglutinin (FHA) in 13vPnC Group Relative to 7vPnC Group
Time frame:
One month after the 3-Dose Infant Series (at 5 months of age) and the Toddler Dose (at 13 months of age)
Reported as:
Number · EU/mL
Geometric Mean Concentration (GMC) as Measured by ELISA for Pertussis Toxin (PT) and Pertussis Filamentous Hemagglutinin (FHA) in 13vPnC Group Relative to 7vPnC Group
EU/mL13vPnC After the Infant Series7vPnC After the Infant Series13vPnC After the Toddler Dose7vPnC After the Toddler Dose
Pertussis - FHA97.12 (89.84 to 104.98)111.23 (102.80 to 120.35)204.28 (185.65 to 224.79)241.08 (210.92 to 275.55)
Pertussis - PT62.94 (58.80 to 67.38)68.20 (63.60 to 73.14)61.09 (56.19 to 66.40)61.70 (54.55 to 69.78)
Statistical analysis
  • 13vPnC After the Infant Series vs 7vPnC After the Infant Series · Ratio: 0.87 · 95% CI 0.78 to 0.98
  • 13vPnC After the Infant Series vs 7vPnC After the Infant Series · Ratio: 0.92 · 95% CI 0.84 to 1.02
  • 13vPnC After the Toddler Dose vs 7vPnC After the Toddler Dose · Ratio: 0.85 · 95% CI 0.72 to 1.00
  • 13vPnC After the Toddler Dose vs 7vPnC After the Toddler Dose · Ratio: 0.99 · 95% CI 0.86 to 1.14
PrimaryPercentage of Participants Achieving a Pneumococcal Antibody Level ≥0.35µg/mL (ELISA) After the 3-Dose Infant Series of 13vPnC

Percentages of participants achieving World Health Organization (WHO) predefined antibody threshold ≥0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

Time frame:
One month after the 3-Dose Infant Series (at 5 months of age)
Reported as:
Geometric mean · percentage of participants
Percentage of Participants Achieving a Pneumococcal Antibody Level ≥0.35µg/mL (ELISA) After the 3-Dose Infant Series of 13vPnC
percentage of participants13vPnC
Common Serotypes - Serotype 4 (n=244)91.4 (87.1 to 94.6)
Common Serotypes - Serotype 6B (n=241)72.6 (66.5 to 78.1)
Common Serotypes - Serotype 9V (n=238)92.9 (88.8 to 95.8)
Common Serotypes - Serotype 14 (n=236)94.9 (91.3 to 97.3)
Common Serotypes - Serotype 18C (n=242)90.5 (86.1 to 93.9)
Common Serotypes - Serotype 19F (n=241)97.9 (95.2 to 99.3)
Common Serotypes - Serotype 23F (n=244)82.8 (77.5 to 87.3)
Additional Serotypes - Serotype 1 (n=240)90.8 (86.5 to 94.2)
Additional Serotypes - Serotype 3 (n=242)96.3 (93.1 to 98.3)
Additional Serotypes - Serotype 5 (n=243)84.0 (78.7 to 88.3)
Additional Serotypes - Serotype 6A (n=243)85.6 (80.5 to 89.8)
Additional Serotypes - Serotype 7F (n=238)97.5 (94.6 to 99.1)
Additional Serotypes - Serotype 19A (n=244)97.5 (94.7 to 99.1)
PrimaryPercentage of Participants Reporting Pre-Specified Local Reactions

Local reactions were collected using an electronic diary. Tenderness (Tender)was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (Sev) (\>7.0 cm). Participants may be represented in more than 1 category.

Time frame:
During the 4-day period after each dose
Reported as:
Number · Percentage of Participants
Percentage of Participants Reporting Pre-Specified Local Reactions
Percentage of Participants13vPnC Dose 17vPnC Dose 113vPnC Dose 27vPnC Dose 213vPnC Dose 37vPnC Dose 313vPnC/13vPnC Toddler Dose7vPnC/7vPnC Toddler Dose7vPnC/13vPnC Toddler Dose
Tender-Any (n=256,257,223,225,210,206,189,96,89)38.338.533.242.236.232.050.344.864.0
Tender-Sig (n=237,245,203,208,188,193,155,86,75)5.54.95.46.73.73.15.24.78.0
Swelling-Any (n=254,256,226,235,217,219,185,99,97)41.338.750.054.548.451.153.557.659.8
Swelling-Mild(n=249,255,223,232,213,214,181,99,95)36.935.746.651.344.645.848.155.657.9
Swelling-Mod (n=243,246,207,208,193,194,159,88,82)14.49.314.014.414.016.019.515.920.7
Swelling-Sev (n=235,244,199,203,184,188,152,87,73)0.00.00.00.00.00.00.70.00.0
Redness-Any (n=256,260,236,241,226,223,187,106,99)44.546.953.458.155.859.266.860.463.6
Redness-Mild(n=252,259,234,240,223,221,180,106,95)40.945.650.956.752.555.760.054.760.0
Redness-Mod (n=241,245,205,206,190,192,165,87,79)9.53.77.36.88.912.524.218.420.3
Redness-Sev (n=234,244,199,203,184,188,152,86,73)0.00.00.00.00.00.00.70.00.0
PrimaryPercentage of Participants Reporting Pre-Specified Systemic Events

Systemic events (fever \[fv\] ≥ 37.5 degrees Celsius \[C\], fever ≥ 38 C but ≤ 39 C, fever \>39 C but ≤ 40 C, fever \> 40 C, decreased \[decr\] appetite, irritability, increased \[incr\] sleep, decreased sleep, hives, use of medication \[med\] to treat symptoms \[sx\], and use of medication to prevent symptoms) were reported using an electronic diary. Participants may be represented in more than 1 category.

Time frame:
During the 4-day period after each dose
Reported as:
Number · Percentage of Participants
Percentage of Participants Reporting Pre-Specified Systemic Events
Percentage of Participants13vPnC Dose 17vPnC Dose 113vPnC Dose 27vPnC Dose 213vPnC Dose 37vPnC Dose 313vPnC/13vPnC Toddler Dose7vPnC/7vPnC Toddler Dose7vPnC/13vPnC Toddler Dose
Fv≥38°C,≤39°C(n=244,250,212,217,201,208,174,99,83)13.510.019.825.326.927.936.841.442.2
Fv>39°C,≤40°C(n=238,245,201,205,184,191,153,89,73)0.80.41.02.40.51.64.62.24.1
Fv >40°C (n=238,245,200,205,184,190,153,88,73)0.00.00.00.00.50.00.70.00.0
Decr appetite(n=243,251,211,218,194,199,167,96,83)24.723.118.526.123.221.129.334.431.3
Irritability (n=261,265,232,238,217,211,178,99,91)54.452.548.349.641.940.350.646.550.5
Incr sleep (n=256,259,215,227,194,204,163,92,81)34.041.328.432.223.728.421.523.923.5
Decr sleep (n=246,253,,215,218,203,196,168,93,81)28.020.626.527.125.120.926.222.630.9
Med-treat sx(n=248,259,224,227,202,214,180,100,89)29.032.838.444.536.142.147.854.055.1
Med-prevent sx(n=252,260,221,236,201,213,181,99,8534.534.636.740.328.437.638.744.440.0
PrimaryGeometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After the 3-Dose Infant Series of 13vPnC

Antibody GMC for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% confidence intervals (CI) were evaluated.

Time frame:
One month after the 3-Dose Infant Series (at 5 months of age)
Reported as:
Geometric mean · μg/mL
Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After the 3-Dose Infant Series of 13vPnC
μg/mL13vPnC
Common Serotypes - Serotype 4 (n=244)1.29 (1.14 to 1.46)
Common Serotypes - Serotype 6B (n=241)0.74 (0.62 to 0.89)
Common Serotypes - Serotype 9V (n=238)1.15 (1.03 to 1.28)
Common Serotypes - Serotype 14 (n=236)2.74 (2.38 to 3.16)
Common Serotypes - Serotype 18C (n=242)1.42 (1.26 to 1.60)
Common Serotypes - Serotype 19F (n=241)1.55 (1.42 to 1.70)
Common Serotypes - Serotype 23F (n=244)0.92 (0.80 to 1.06)
Additional Serotypes - Serotype 1 (n=240)1.21 (1.07 to 1.38)
Additional Serotypes - Serotype 3 (n=242)1.25 (1.13 to 1.37)
Additional Serotypes - Serotype 5 (n=243)0.93 (0.82 to 1.06)
Additional Serotypes - Serotype 6A (n=243)0.94 (0.82 to 1.06)
Additional Serotypes - Serotype 7F (n=238)1.93 (1.73 to 2.15)
Additional Serotypes - Serotype 19A (n=244)2.10 (1.87 to 2.35)

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
13vPnC Infant Series—5/304 (1.6%)142/304 (46.7%)
7vPnC Infant Series—5/309 (1.6%)162/309 (52.4%)
13vPnC Post-Infant Series—8/290 (2.8%)12/290 (4.1%)
7vPnC Post-Infant Series—5/299 (1.7%)11/299 (3.7%)
13vPnC/13vPnC Toddler Dose—2/273 (0.7%)125/272 (46%)
7vPnC/7vPnC Toddler Dose—0/152 (0%)64/152 (42.1%)
7vPnC/ 13vPnC Toddler Dose—2/134 (1.5%)63/137 (46%)
13vPnC / 13vPnC 6-Month Follow-up—6/267 (2.2%)2/267 (0.7%)
7vPnC / 7vPnC 6-Month Follow-up—1/150 (0.7%)2/150 (1.3%)
7vPnC / 13vPnC 6-Month Follow-up—0/133 (0%)2/133 (1.5%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
Event13vPnC Infant Series7vPnC Infant Series13vPnC Post-Infant Series7vPnC Post-Infant Series13vPnC/13vPnC Toddler Dose7vPnC/7vPnC Toddler Dose7vPnC/ 13vPnC Toddler Dose13vPnC / 13vPnC 6-Month Follow-up7vPnC / 7vPnC 6-Month Follow-up7vPnC / 13vPnC 6-Month Follow-up
GastroenteritisInfections and infestations1/3041/3092/2901/2990/2730/1521/1342/2670/1500/133
BronchiolitisInfections and infestations2/3041/3091/2900/2990/2730/1521/1340/2671/1500/133
Lung disorderRespiratory, thoracic and mediastinal disorders0/3040/3090/2900/2990/2730/1521/1340/2670/1500/133
AsthmaRespiratory, thoracic and mediastinal disorders0/3040/3091/2900/2990/2730/1520/1340/2671/1500/133
DehydrationMetabolism and nutrition disorders0/3040/3090/2900/2990/2730/1520/1341/2670/1500/133
Otitis media acuteInfections and infestations0/3040/3090/2900/2990/2730/1520/1341/2670/1500/133
PneumoniaInfections and infestations0/3040/3090/2900/2990/2730/1520/1341/2670/1500/133
PyelonephritisInfections and infestations0/3041/3090/2901/2990/2730/1520/1341/2670/1500/133
Gastroenteritis bacterialInfections and infestations0/3040/3090/2900/2991/2730/1520/1340/2670/1500/133
HypotoniaNervous system disorders0/3040/3090/2900/2991/2730/1520/1340/2670/1500/133
Most frequent other events
Showing 10 of 143
Most frequent other events
Event13vPnC Infant Series7vPnC Infant Series13vPnC Post-Infant Series7vPnC Post-Infant Series13vPnC/13vPnC Toddler Dose7vPnC/7vPnC Toddler Dose7vPnC/ 13vPnC Toddler Dose13vPnC / 13vPnC 6-Month Follow-up7vPnC / 7vPnC 6-Month Follow-up7vPnC / 13vPnC 6-Month Follow-up
Erythema (Any)Skin and subcutaneous tissue disorders114/256122/260——125/18764/10663/99———
Tenderness (Any)Skin and subcutaneous tissue disorders98/25699/257——95/18943/9657/89———
Erythema (Mild)Skin and subcutaneous tissue disorders103/252118/259——108/18058/10657/95———
Induration (Any)Skin and subcutaneous tissue disorders105/25499/256——99/18557/9958/97———
Erythema (Any)Skin and subcutaneous tissue disorders126/226132/223———————0/133
Erythema (Any)Skin and subcutaneous tissue disorders126/236140/241————————
Induration (Mild)Skin and subcutaneous tissue disorders92/24991/255——87/18155/9955/95———
Erythema (Mild)Skin and subcutaneous tissue disorders119/234136/240————————
Erythema (Mild)Skin and subcutaneous tissue disorders117/223123/221————————
Induration (Any)Skin and subcutaneous tissue disorders113/226128/235————————

Baseline characteristics

Age Continuous
Age Continuous(months)13vPnC/13vPnC Vaccine7vPnC/7vPnC VaccineTotal
Mean2.1 ± 0.52.1 ± 0.52.1 ± 0.5
Sex: Female, Male
Sex: Female, Male(Participants)13vPnC/13vPnC Vaccine7vPnC/7vPnC VaccineTotal
Female169164333
Male135145280
08

Study locations

46 sites
  • Albi, 81000, France
  • Amiens, 80000, France
  • Ancenis, 44150, France
  • Blanquefort, 33370, France
  • Bondues, 59910, France
  • Bordeaux, 33000, France
  • Brest, 29200, France
  • Chalons en champagne, 51000, France
  • Creteil, 94000, France
  • Dijon, 21000, France
  • Draguignan, 83300, France
  • Ecully, 69130, France
  • Essey-les-nancy, 54270, France
  • Floirac, 33270, France
  • Frejus, 83600, France
  • Garges-les-Gonesse, 95140, France
  • Illkirch, 67400, France
  • Joue les tours, 37300, France
  • Le havre, 76600, France
  • Le plessis-trevise, 94420, France
  • Le pontet, 84130, France
  • Les lilas, 93260, France
  • Les sables d'olonne, 85100, France
  • Libourne, 33500, France
  • Lingolsheim, 67380, France
  • Lyon, 69005, France
  • Lyon, 69007, France
  • Marcq en baroeul, 59700, France
  • Maromme, 76150, France
  • Moutiers, 73600, France
  • Nancy, 54000, France
  • Nice, 06300, France
  • Nogent sur marne, 94130, France
  • Nogent-sur-marne, 94130, France
  • Oullins, 69600, France
  • Paris, 75571, France
  • Rouen, 76100, France
  • Strasbourg, 67000, France
  • Strasbourg, 67100, France
  • Thionville, 57100, France
  • Tours, 37000, France
  • Tresses melac, 33370, France
  • Vandoeuvre les nancy, 54500, France
  • Vaulx-en-velin, 69120, France
  • Villeneuve d'ascq, 59650, France
  • Vitry-sur-seine, 94400, France
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2006, a primary completion of Nov 2008 and a completion of Nov 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2012, 3 years 9 months after primary completion. A results delay was requested in Feb 2009.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2006
First posted
Aug 21, 2006
Start
Oct 2006
Primary completionActual
Nov 2008
CompletionActual
Nov 2008
Results delay requested
Feb 26, 2009
Results first posted
Aug 15, 2012
Last update
Aug 15, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00366678
Responsible party
Sponsor
First posted
Aug 21, 2006
Start date
Oct 2006
Primary completion
Nov 2008
Completion
Nov 2008
Results posted
Aug 15, 2012
Last update
Aug 15, 2012

Study contacts

Medical Monitor
study director · Wyeth is now a wholly owned subsidiary of Pfizer
Trial Manager
principal investigator · For France, infomedfrance@wyeth.com

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 13-valent pneumococcal vaccine

Start the discussion